PMID- 27043841
OWN - NLM
STAT- MEDLINE
DCOM- 20170531
LR  - 20181113
IS  - 1179-2000 (Electronic)
IS  - 1177-1062 (Linking)
VI  - 20
IP  - 3
DP  - 2016 Jun
TI  - A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and 
      Prediction of Responses to Anti-TNF-alpha and Anti-IL-12/23 Agents.
PG  - 221-5
LID - 10.1007/s40291-016-0198-z [doi]
AB  - INTRODUCTION: Psoriasis is a highly divergent disease with many disease 
      phenotypes, but there are currently no established biomarkers to predict the 
      therapeutic outcomes of systemic treatments. With the introduction of biologic 
      therapies during the last decade and with new treatments constantly emerging, 
      there is a great need to validate biomarkers that have been reported to be 
      associated with treatment response, and to introduce new biomarkers of possible 
      clinical value. METHODS: In the current study, we aimed to investigate the 
      association of psoriasis-related polymorphisms that have previously been reported 
      to effect the anti-tumor necrosis factor alpha (anti-TNF-alpha) therapies 
      (etanercept, adalimumab, and infliximab) and anti-interleukin-12/23 
      (anti-IL-12/23) biologic therapy (ustekinumab) in a Greek cohort of psoriasis 
      patients. RESULTS: Rs10484554 in the HLA-C gene showed an association with a good 
      response to anti-TNF-alpha agents but not to ustekinumab, while rs151823 and rs26653 
      in the ERAP1 gene showed associations with a good response to anti-IL-12/23 
      therapy. CONCLUSION: This study is the first in the field of pharmacogenetics in 
      Greek psoriasis patients. Further, larger studies are required to validate our 
      findings and replicate them in various populations.
FAU - Masouri, Sofia
AU  - Masouri S
AD  - Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical 
      School, Dragoumi 5, Athens, 161 21, Greece. sofimasouri@yahoo.gr.
FAU - Stefanaki, Irene
AU  - Stefanaki I
AD  - Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical 
      School, Dragoumi 5, Athens, 161 21, Greece.
FAU - Ntritsos, Giorgos
AU  - Ntritsos G
AD  - Department of Hygiene and Epidemiology, University of Ioannina Medical School, 
      Ioannina, Greece.
FAU - Kypreou, Katerina P
AU  - Kypreou KP
AD  - Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical 
      School, Dragoumi 5, Athens, 161 21, Greece.
FAU - Drakaki, Eleni
AU  - Drakaki E
AD  - Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical 
      School, Dragoumi 5, Athens, 161 21, Greece.
FAU - Evangelou, Evangelos
AU  - Evangelou E
AD  - Department of Hygiene and Epidemiology, University of Ioannina Medical School, 
      Ioannina, Greece.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial 
      College London, London, UK.
FAU - Nicolaidou, Electra
AU  - Nicolaidou E
AD  - Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical 
      School, Dragoumi 5, Athens, 161 21, Greece.
FAU - Stratigos, Alexandros John
AU  - Stratigos AJ
AD  - Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical 
      School, Dragoumi 5, Athens, 161 21, Greece.
FAU - Antoniou, Christina
AU  - Antoniou C
AD  - Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical 
      School, Dragoumi 5, Athens, 161 21, Greece.
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Mol Diagn Ther
JT  - Molecular diagnosis & therapy
JID - 101264260
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Interleukin-23)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 187348-17-0 (Interleukin-12)
RN  - FU77B4U5Z0 (Ustekinumab)
SB  - IM
MH  - Alleles
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - *Genetic Variation
MH  - Genotype
MH  - Greece
MH  - Histocompatibility Antigens Class I/genetics
MH  - Humans
MH  - Interleukin-12/*antagonists & inhibitors
MH  - Interleukin-23/*antagonists & inhibitors
MH  - *Pharmacogenomic Variants
MH  - Polymorphism, Single Nucleotide
MH  - Psoriasis/*drug therapy/*genetics
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Ustekinumab/pharmacology/therapeutic use
EDAT- 2016/04/05 06:00
MHDA- 2017/06/01 06:00
CRDT- 2016/04/05 06:00
PHST- 2016/04/05 06:00 [entrez]
PHST- 2016/04/05 06:00 [pubmed]
PHST- 2017/06/01 06:00 [medline]
AID - 10.1007/s40291-016-0198-z [pii]
AID - 10.1007/s40291-016-0198-z [doi]
PST - ppublish
SO  - Mol Diagn Ther. 2016 Jun;20(3):221-5. doi: 10.1007/s40291-016-0198-z.